Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Failure NYHA Class III Clear all
Terminated No phase listed Observational

PRODIGY Registry in NYHA Class III Heart Failure Patients

NCT03623165
View directory record Official record
Conditions
Heart Failure NYHA Class III
Interventions
Cordella™ Heart Failure System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 22, 2026, 5:19 PM EDT
Not listed Phase 1Phase 2 Interventional

Biomarker Study: Heart Failure Patients at Risk

NCT05336175
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Angiotensin 1-7, Saline solution
Drug
Lead sponsor
University of Arizona
Other
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C

NCT01381172
View directory record Official record
Conditions
NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Interventions
Optimizer System, No intervention: Optimal medical therapy
Device · Other
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
32
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 22, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

NCT00283361
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination
Drug · Procedure · Behavioral
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2007 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

NCT00531661
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
HF Pressure Measurement System
Device
Lead sponsor
CardioMEMS
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Nationwide, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 22, 2026, 5:19 PM EDT
Not listed Not applicable Interventional

Feasibility Study of the Intravascular Ventricular Assist System (iVAS)

NCT02645539
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
intravascular ventricular assist system (iVAS)
Device
Lead sponsor
NuPulseCV
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 22, 2026, 5:19 PM EDT
Withdrawn Phase 2 Interventional

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

NCT07221513
View directory record Official record
Conditions
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions
JK07
Drug
Lead sponsor
Salubris Biotherapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

NCT05934487
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Completed No phase listed Observational

REGISTRY EVALUATION OF VITAL INFORMATION FOR VADs IN AMBULATORY LIFE

NCT01369407
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
No Intervention
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Beverly Hills, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Cognitive Intervention to Improve Memory in Heart Failure Patients

NCT03035565
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class I
Interventions
Computerized Cognitive Training with Brain HQ, Computerized Crossword Puzzles
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 22, 2026, 5:19 PM EDT
Withdrawn Phase 2 Interventional

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184
View directory record Official record
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 22, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Sustaining Home Heart Failure Palliative Care in Rural Appalachia

NCT06791850
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
HF-FamPALhomeCARE
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
45 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Active, not recruiting Phase 2 Interventional

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
AB-1002
Drug
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 22, 2026, 5:19 PM EDT
Recruiting No phase listed Observational

Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure

NCT06783335
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure
Interventions
Cordella PA Sensor System, Standard of Care Pharmacologic Therapy
Device · Drug
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Phase 2 Interventional

Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device

NCT00957541
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Paradym CRT + Physiological Diagnosis (PhD)
Device
Lead sponsor
ELA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 22, 2026, 5:19 PM EDT
Not listed Phase 3 Interventional

Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D

NCT01534234
View directory record Official record
Conditions
Heart Failure NYHA Class III and Ambulatory IV
Interventions
PARADYM RF SONR
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 22, 2026, 5:19 PM EDT
Not listed Not applicable Interventional

Effect of DASH Eating Pattern on Heart Failure Outcomes

NCT03538990
View directory record Official record
Conditions
Heart Failure NYHA Class III
Interventions
DASH Eating Pattern
Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Not applicable Interventional

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

NCT01900600
View directory record Official record
Conditions
Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions
Cardiopulmonary exercise test, Echocardiogram
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 110 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Phase 1 Interventional

AB-1002 in Patients With Class III Heart Failure

NCT04179643
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure，Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
Interventions
3 x 10e13vg AB-1002
Biological
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Minneapolis, Minnesota • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Recruiting Not applicable Interventional

Promoting Well-being and Health in Heart Failure

NCT04829617
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
PP-MI Intervention, MI-alone Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure

NCT01357850
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
GSK716155, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Savannah, Georgia • Metairie, Louisiana • Auburn, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 22, 2026, 5:19 PM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

NCT06859970
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Interventions
PAS-C System
Device
Lead sponsor
InterShunt Technologies, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Jonesboro, Arkansas • Thousand Oaks, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 22, 2026, 5:19 PM EDT
Terminated Phase 2 Interventional

Study of DITPA in Patients With Congestive Heart Failure

NCT00103519
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
DITPA (3,5-diiodothyropropionic acid), Placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 22, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 22, 2026, 5:19 PM EDT